

Identification of Methicillin Resistance *Staphylococcus aureus* in Immunocompromised Host Using PCR Technique and Detection of Its Sensitivity to Antibiotics

Noor M. Abdullah

Amna N. Jassim

Abaas A. Alani

University of Baghdad,
College of Science for women

Abstract

Two hundred and twenty clinical specimens were collected from were collected from patients in Medical City Hospitals (Baghdad /Iraq). During the period From November 2013 to April 2014. The specimens were included (54) ear swab, (56) blood, (70) burn swab, and (40) urine sample. It was found that (49.03%) of the 108 isolates were belong to *Staphylococcus* spp., were diagnosed as coagulase-positive staphylococci (COPS), where 112 (50.9%) of clinical samples were coagulase negative (CONS). From the collected clinical samples, 85(78.7%) were MRSA according to sensitivity test and vitek system, and the rest were MSSA 23(21.9%).

In the present study, ceftaroline is drug of choice, because of it activity against Methicillin-resistant *S. aureus* .The effectiveness of the ceftaroline antibiotic are being tested on 85 isolate of Methicillin-resistant *S. aureus* (MRSA), all isolate were sensitive to ceftaroline.

Keywords: *S. aureus*. MRSA, Ceftaroline, Susceptibility test.

Introduction

The *S. aureus* bacterium is a serious human pathogen that causes life-threatening nosocomial and community associated infections (1). Staphylococcal infection can affect many sites and organs of the human body. Invasion of the skin cause impetigo, cellulitis. In the lungs abscesses and pneumonia are the result. Infection of the heart leads to endocarditis. Meningitis and abscess formation can be the result of infection to the

central nervous system as well as, keratitis can be the result of eye infection (2).

S. aureus are grouped into two major classes: Methicillin Sensitive *S. aureus* (MSSA) and Methicillin Resistant *S. aureus* (MRSA). MRSA strains have been associated with nosocomial or hospital acquired infections world over and have also emerged as an important cause of community acquired infections (3). Resistance to methicillin is mostly determined by the presence of *mecA* gene encoding altered penicillin binding protein which shows low affinity to β -lactam antibiotics (4). The *mecA* gene, which originates from a mobile genetic element named the staphylococcal cassette chromosome *mec* [SCC*mec*] invariably inserted into the *orfX* gene of methicillin-resistant staphylococci, is the genetic basis of methicillin resistance (5, 6).

Vancomycin has been the cornerstone of treatment of patients with serious MRSA infections. Consequently, vancomycin use has been increasing since the mid-1980's, resulting in the emergence of MRSA with reduced susceptibility to vancomycin (7). However many researchers have been noted MRSA that resistant to vancomycin (8,9).

The cephalosporin class of antimicrobial agents is known for its broad spectrum of activity, proven efficacy and favourable safety profile, making it the most commonly prescribed class of antimicrobials (10). Ceftaroline fosamil is a cephalosporin prodrug whose active principle, ceftaroline (CPT), is active against MRSA and drug-resistant *S. pneumoniae* (11). This compound has the distinction of being the first anti-MRS β -lactam to be marketed in the USA (2010), where it received FDA approval for treatment of acute bacterial skin and skin structure infections (SSSI) and for community-acquired pneumonia (CAP) (12). Ceftaroline shows good clinical efficacy against (MRSA) due to its ability to bind to PBP2A (13)

Materials and Methods

Staphylococcus aureus isolation and identification

Specimen's collection: From November 2013 to April 2014, Two hundred and twenty specimens were collected from patients in Medical City Hospitals (Baghdad /Iraq). The specimens were included (54) ear swab, (56) blood, (70) burn swab, and (40) urine sample.

Isolation: The collected specimens were inoculated on the blood agar, incubated at 37°C for 24 hours. The isolates were examined for their haemolytic activity. Then transferred and streaked on mannitol salt agar,

and to detecting the ability of each isolate to ferment mannitol. All plates were incubated at 37°C for 24 hours, then transfer a single pure isolated colony to nutrient agar medium for the preservation and to Completion other biochemical tests that confirmed the identification of isolates.

Identification of *Staphylococcus aureus*

1- Gram's stain: The isolates were stained by Gram stain to detect their grape-like clusters of blue color under microscopic examination (14).

2- Cultural characteristics: Different cultural characteristics (color, shape, edge, and size) of *S. aureus* was studied on the growth media (mannitol salt agar and blood agar) (15).

3-Biochemical tests (Catalase test, Tube coagulase test, Oxidase test, and Mannitol (fermentation test) .

4- Susceptibility test. 5- Vitak II system.

DNA Extraction

DNA Extraction from Bacterial isolates

DNA extracted and purified by using Wizard® genomic DNA purification kit (promega, Madison, WI, USA).

Specific primers: *MecA* primer

Sequences of oligonucleotide primers and their location in the *mecA* gene (16)

Primer	Primer sequence	Product length (basepairs)	Location (nucleotide numbers)
<i>mecA</i>	Mec-A1 (+)AAAATCGATGGTAAAGGTTGGC	533	1282-1303
<i>mecA</i>	Mec-A2 (-) AGTTCTGCAGTACCGGATTTGC	533	1739-1814

Polymerase Chain Reaction (PCR) Technique

Target DNA amplification with a pair of primers, resulting in several copies of the target sequence (17).

Preparation disks of ceftaroline

Ceftaroline stock solution prepared by dissolving 600 mg in 20 ml of D.W. The reconstituted solution is a pale yellow solution that is free of any particles. Each disk should contain 30 Mg of ceftaroline, were prepared according to this equation: $C1 * V1 = C2 * V2$

Statistical Analysis

The Statistical Analysis System- SAS (2012)(18) was used to effect of different factors in study parameters. Chi-square test was used to significant compare between percentage in this study.

Results and Discussion:

Two hundred and twenty clinical samples were collected from different patients, the samples included burn swab, ear swab, urine, and blood table (1).108 (49.03%) of clinical samples were *S. aureus* giving positive result in coagulase test ,catalase test ,and biochemical test ,where 112 (50.9%) of clinical samples were coagulase negative.

Table (1) Prevalence of *S. aureus* isolates among different specimens

Source of sample	Total No.	No. of <i>S. aureus</i> isolates	Percentage (%)
Ear swab	54	23	42.59 %
Blood	56	20	35.7 1%
Urine	40	16	40 %
Burn	70	49	70 %
Total	220	108	49.09%

The highest percentage of MRSA isolates, was from burn samples, it was 93.87% table (2).This high percentage may attributed to that the skin which represent the first line of defense and an example of innate immunity is damaged and the burned parts of patient remain exposed to air, that increase opportunity of infection with pathogenic bacteria .Burns remain considerable serious problem of public health associated with morbidity and mortality ,our Explanation close to the explan of Othman and Kendrick, (2011)(19). Burn patients become susceptible to infection due to the loss of the protective barrier and decreased cellular and humoral immunity (20).Infection remains a major complication in burn patients after initial period of shock and the chance of infection persist until complete wound healing (21).

From the collected clinical samples, 85 (78.7%) where MRSA according to sensitivity test and vitek system, and the rest were MSSA 23(21.9%).Present results were agree with agree with the results of a local study by Al-Maliki, (2009)(22) who showed that the percentage of MRSA to the MSSA were (80.3%, 16.4%) respectively.As well as, Al- Hasani, (2011)(23) reported that the ratio of MRSA was (83.70%). On the other hand, Al-Geobory, (2011)(24) showed that the ratio of MRSA was (90.90%). On the other hand, current results did not agree with the results of peck et al., (2009)(25) which showed that only (51.4%) of isolates were methicillin resistant. Also, the finding of AL-alem, (2008)(26) showed that the ratio of MRSA strain was (56%). These observed differences may due to the variation in the geographic area, sources of clinical specimens, genetic background and the collection site of isolates.

Table (2) Prevalence of MRSA isolates among *S. aureus* isolates

Source of sample	No. of <i>S. aureus</i> isolates	No. of MRSA isolates	Percentage (%)
------------------	----------------------------------	----------------------	----------------

Identification of Methicillin Resistance *Staphylococcus aureus* in Immunocompromised Host Using PCR Technique and Detection of Its Sensitivity to Antibiotics
Noor M. Abdullah , Amna N. Jassim , Abaas A. Alani

Ear swab	23	17	73.91 %
Blood	20	14	70 %
Urine	16	8	50 %
Burn	49	46	93.87 %
Total	108	85	78.7 %

Susceptibility of *S. aureus* isolates was detected against (10) types of antibiotics, the tested pathogenic isolates were found to exhibit obvious level of resistance against the used antibiotics and the susceptibility pattern for these clinical *S. aureus* isolates are shown in table (3). In this study the results demonstrated that out of (108) tested *S. aureus* isolates that were isolated from(4) sources, about (85) isolates showed a high level of resistance to Penicillin G , Chloramphenicol, Cefoxitin, Oxacillin , and Methicillin respectively table(3) .

Table (3) Resistance & Sensitive to Difference Antibiotic Used for Sensitivity Test of *S. aureus* Isolates

Antibiotic	Resistance	Intermediate	Sensitive
Gentamycin	60 (55.56%)	12 (11.11%)	36 (33.33%)
Erythromycin	70 (64.81%)	8 (7.41%)	30 (27.78%)
Clindamycin	81 (75.00%)	18 (16.67%)	9 (8.33%)
Cefoxitin	89 (82.41%)	2 (1.85%)	17 (15.74%)
Chloramphenicol	90 (83.33%)	0 (0.00%)	18 (16.67%)
Penicillin G	90 (83.33%)	0 (0.00%)	18 (16.67%)
Oxacillin	86 (79.63%)	0 (0.00%)	22 (20.37%)
Vancomycin	24 (22.22%)	0 (0.00%)	84 (77.78%)
Tetracyclin	82 (75.92%)	6 (5.56%)	20 (18.52%)
Methicillin	85 (78.70%)	3 (2.78%)	20 (18.52%)

The vitak- 2 Compact was used to confirm the identification and typing of MRSA isolates which previously identified by conventional biochemical tests, the result from vitak- 2 were closely with those obtained from sensitivity test for same antibiotics that used in both tests.

A confirmatory test was carried out for the selected isolates using PCR technique for further characterization up to the species level by the amplification of (mecA) gene ,and all the isolates are found to be positive for the presence of (mecA) gene figure(1).




Figure (1) Agarose gel electrophoresis of PCR product amplified from *mecA* genes. These genes from MRSA isolates. M = DNA marker fragments. Lane 1, 2, 3 & 4 indicate the *mecA* positive samples, 5 negative control. The DNA fragments of 533 bp were amplified from *mecA* gene.

In the present study, ceftaroline is drug of choice, because of its activity against MRSA. The effectiveness of the ceftaroline antibiotic are being tested on 85 isolate of MRSA, 39 (45.88%) isolates gave 32 mm diameter inhibition zone, 18 (21.17%) isolates gave 30 mm diameter inhibition zone, 8 (9.4%) isolates gave 28 mm diameter inhibition zone, 7 (8.2%) isolates gave 27 mm diameter inhibition zone, and 13 (15.29%) isolates gave 26 mm diameter inhibition zone figure (2). All 85 isolate of (MRSA) are sensitive to ceftaroline, so ceftaroline has demonstrated bactericidal in vitro activity against MRSA, and this conclusion agree with (27,28)



Figure (2) The effect of ceftaroline on MRSA with bactericidal in vitro activity

In the present study the pattern of minimum inhibitory concentration of *S.aureus* isolates to ceftaroline, was determined using MIC method; the results revealed that MIC range from (0.5 µg/ml - 0.12 µg/ml), for 81 (95.29%) MRSA isolates the MIC (0.5 µg/ml), 3 (3.52%) MRSA isolates the MIC (0.25 µg/ml), and 1 (1.17%) MRSA isolate the MIC (0.12 µg/ml). MIC results for the tested clinical isolates are summarized in table (4).

Table (4) MIC Values of Ceftaroline

MIC	No. of isolates	Percentage (%)
0.5 µg/ml	81	95.29%
0.25 µg/ml	3	3.52%
0.12 µg/ml	1	1.17%

Ceftaroline demonstrated good activity against MRSA, Its in vitro activity against MRSA is related to its high affinity for PBP2a, (29). Different ceftaroline MICs value depending on geographical location (30), and inverse correlation between PBP2a binding affinity and ceftaroline MIC, which is expected because the anti-MRSA activity of ceftaroline reflects binding and inhibition of PBP2a (31). Data from case series suggest that ceftaroline is safe and effective for severe MRSA infections with success rates in over 70% of cases (32,33), and Polenakovik and Pleiman, 2013). To date, clinical trials have demonstrated efficacy of ceftaroline similar to that of comparator agents in the treatment of ABSSSI and CABP. Clinical trials suggest that ceftaroline is well tolerated common to the cephalosporin class. Overall, the most common adverse events occurring in more than 2% of patients in clinical trials were diarrhea, nausea, and rash (34).

References

- 1- **Anstead, G.M.**; Cadena, J. and Javeri, H. (2014). Treatment of infections due to resistant *Staphylococcus aureus*. Methods Mol. Biol. 1085, 259–309.
- 2- **Rahman, M.D.A.** (2011). Species distribution, antimicrobial susceptibility and some virulence Factors of Coagulase-negative Staphylococci isolated from different clinical specimens at Mymensingh Medical College, Mymensingh. M.Sc. Thesis. Medical College of Mymensingh. University of Mymensingh (Bangladesh).
- 3- **Beilman, G.J.** ; Sandifer, G.; Skarda, D.; Jensen, B.; McAllister, S.; Killgore, G. and Srinivasan, A. (2005). Emerging infections with community-associated methicillin-resistant *Staphylococcus aureus* in outpatients at an Army Community Hospital, Surg Infect (Larchmt), 6:87-92.
- 4- **Chambers, H.F.** (1997). Methicillin resistance in Staphylococci: Molecular and biochemical basis and clinical implications, Clin Microbiol Rev. 1:781-91.
- 5- **Katayama, Y.**; Takeuchi, F.; Ito, T.; Ma, X.X.; Ui- Mizutani, Y.; Kobayashi, Y. and Hiramatsu, K. (2003). Identification in methicillin-susceptible *Staphylococcus hominis* of an active primordial mobile genetic element for the staphylococcal cassette chromosome mec of methicillin-resistant *Staphylococcus aureus*. Journal of Bacteriology, 185: 2711–2722.
- 6- Patrice, F.; Bento, M.; Renzi, G.; Harbarth, S.; Pittet, D. and Schrenzel, J. (2013). Evaluation of Three Molecular Assays for Rapid Identification of Methicillin-Resistant *Staphylococcus aureus*. Journal of Clinical Biology, 45: 2011-2013.
- 7- **Dhand, A.** and Sakoulas, G. (2012). Reduced vancomycin susceptibility among clinical *Staphylococcus aureus* isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep. 4: 4.
- 8- **Abbas, Y.A.**; Nasir, R.J. and Muhalab, T. (2012). Detection of Toxic Shock Syndrome Toxin Genes in Enterotoxin Producing *Staphylococcus aureus* Isolated from Food and Food's Workers. J. Col. Edu. 2 (2):108-120.
- 9- **Mohammed, S.M.** (2011). Use of Cefoxitin as indicator for detection of Methicillin Resistant *Staphylococcus aureus*. Baghdad Science Journal. 8 (4): 947-955.
- 10- **Clavenna, A.**; Sequi, M. and Bonati, M. (2010). Differences in the drug prescriptions to children by Italian paediatricians and general practitioners. Eur J. Clin Pharmacol. 66: 519–24.
- 11- **Goodman, J.J.** and Martin, S.I. (2012) Critical appraisal of ceftaroline in the management of community acquired bacterial pneumonia and skin infections. Ther. Clin. Risk Manag. 8:149–156.

Identification of Methicillin Resistance *Staphylococcus aureus* in Immunocompromised Host Using PCR Technique and Detection of Its Sensitivity to Antibiotics
Noor M. Abdullah , Amna N. Jassim , Abaas A. Alani

- 12- **Corey, G.R.;** Wilcox, M.H.; Talbot, G.H.; Thye, D.; Friedland, D. and Baculik, T. (2010). CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. *J. Antimicrob Chemother.* 65 Suppl 4:iv41–iv51.
- 13- **Bassetti, M.;** Ginocchio, F.; Mikulska, M.; Taramasso, L. and Giacobbe, D.R. (2011). Will new antimicrobials overcome resistance among gram-negatives? *Expert Rev. Anti-Infect. Ther.* 9, 909–922.
- 14- **Subhankari, P. C.;** Santanu, K. M. and Somenath, R. (2011). Biochemical characters and antibiotic susceptibility of *Staphylococcus aureus* isolates. *Asian Pacific Journal of Tropical Biomedicine.* India. 212–216.
- 15- **Koneman, E.;** Procop, G.; Schreckenberger, P.; Woods, G.; Winnw, W.; Allen, S. and Janda, W. (2006). *Koneman's color atlas and textbook of diagnostic microbiology.* (6th Ed.). Lippincott Williams and willkins. Philadelphia. Baltimore. New York. London.
- 16- **Islam, M.A.;** Alam, M.M.; Uddin, M.S.; Kobayashi, N. and Ahmed, M.U. (2011). Detection of Methicillin-Resistant *Staphylococcus aureus* (Mrsa) from Animal and Human Origin in Bangladesh by Polymerase Chain Reaction. *Bangl. J. Vet. Med.* 9 (2): 161 – 166.
- 17- **Al-khafaji, M.H.M.** (2013). Detection of enterotoxins genes in *Staphylococci* isolated from milk and cheese. Ph.D. thesis. College of Science. Baghdad University.
- 18- **SAS. (2012).** Statistical Analysis System, User's Guide. Statistical. Version 9.1th ed. SAS. Inst. Inc. Cary. N.C. USA.
- 19- **Othman, N. and Kendrick, D.** (2011). Burns in Sulaymaniyah province, Iraq: epidemiology and risk factors for death in patients admitted to hospital. *J. Burn. Care Res.* 32(4):126-134.
- 20- **Wong, T. H.;** Tan, B. J.; Ling, M. L. and Song, C. (2002). Multi-resistant *Acinetobacter baumannii* on burns unit-clinical risk factors and progenosis. *Burns.* 28(4).
- 21- **Kaushik, R.;** Kumar, S.; Sharma, R. and Lal, P. (2001). Bacteriology of burn wounds, the first three years in a new burn unit at Medical College Chandigarh. *Burns.* 27(6):595-597.
- 22- **Al-Maliki, A.A.A.** (2009). A Study of some Methicillin-Resistant *Staphylococci* (MRSA) and (MRSE) isolated from Baghdad hospital patients. M.Sc. Thesis. College of Science. AL-Mustansiriya University
- 23- **Al-Hasani, H. M. H.** (2011). Comparative Study between Methicillin-Resistant Coagulase Positive and Negative *Staphylococci*. M.Sc. Thesis. College of Science. University of Baghdad.
- 24- **Al-Geobory, H. A. H.** (2011). Comparative study between Methicillin resistant *Staphylococcus aureus* (MRSA) and Methicillin sensitive *Staphylococcus aureus* (MSSA), and detect the antimicrobial effects of some plant extracts on them. M.Sc. Thesis. College of Science. University of Baghdad.
- 25- **Peck, K. R.;** Baek, J. Y.; Song, J-H. and Ko, K. S. (2009). Comparison of genotypes and enterotoxin genes between *Staphylococcus aureus* isolates from blood and nasal colonizers in Korean hospitals. *J. Korean. Med. Sci.* 24:585-591.
- 26- **Al-Alem, A.H.** (2008). Antibiotic resistant *Staphylococcus aureus* infection studies in hospitals .ph.D. Thesis. Department of Biochemistry. Middle East Technical University.
- 27- **Saravolatz, L.;** Pawlak, J. and Johnson, L. (2010). In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin- intermediate, vancomycin-resistant, and daptomycin-nonsusceptible *Staphylococcus aureus* isolates. *Antimicrob. Agents Chemother.* 54:3027– 3030.
- 28- **Zhanel, G.G.;** Rossnagel, E.; Nichol, K.; Cox, L.; Karlowsky, J.A.; Zelenitsky, S.; Noreddin, A.M. and Hoban, D.J. (2011). Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant *Staphylococcus aureus*, heteroresistant vancomycin-intermediate *S. aureus*, vancomycin-intermediate *S. aureus* and vancomycin-resistant *S. aureus* using an in vitro model. *J. Antimicrob. Chemother.* 66:1301– 1305.
- 29- **Moisan, H.;** Pruneau, M. and Malouin, F. (2010) Binding of ceftaroline to penicillin-binding proteins of *Staphylococcus aureus* and *Streptococcus pneumoniae*. *J Antimicrob Chemother* 65: 713–6.
- 30- **Richard A. A.;** Robert E. M.; Veronica N. K.; Helio S. S.; Joseph P. I. and Sushmita D. L. (2014). Analysis of *Staphylococcus aureus* clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. *Oxford Journals. Antimicrob. Chemother.* 69 (8): 2065-2075.
- 31- **Rodrigo, E. M.;** Athanassios, T.; Helio, S. S.; Ronald, N. J.; Donald, B.; Pamela, M.; Peter, C. A. and Klaudia, K. (2012). Characterization of methicillin-resistant *Staphylococcus aureus* displaying increased MICs of ceftaroline. *J Antimicrob Chemother* . 67: 1321–1324
- 32- **Casapao, A.M.;** Davis, S.L. and Barr, V.O., et al. (2014). A large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. *Antimicrob Agents Chemother*; 58:2541–6
- 33- **Polenakovik, H.M. and Pleiman, C.M.** (2013) Ceftaroline for methicillin-resistant *Staphylococcus aureus* bacteraemia: case series and review of the literature. *Int J Antimicrob Agents* . 42:450–5.
- 34- **Margaret R. J.;** Daryl D. D. and Peggy L. C. (2011). Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant *Staphylococcus aureus* . *The Annals of Pharmacotherapy*. 45:1398-1384.

**التعرف على بكتريا العنقوديات الذهبية المقاومة للميثيسيلين في الاشخاص
المثبطين مناعيا باستخدام تفاعل البلمرة المتسلسل والتحري عن
حساسيتها للمضادات الحيوية**

نور ماجد عبد الله أ.د. امه نصيف جاسم أ.د. عباس عبد المعيد مصطفى
الخلاصة

شملت هذه الدراسة جمع (٢٠٦) عينة من مرضى يعانون من امراض ضعف المناعة في مستشفى مدينة الطب (العراق/ بغداد)، خلال الفترة من شهر تشرين الثاني / ٢٠١٣ الى شهر نيسان / ٢٠١٤. تضمنت العينات (٧٠) مسحة من الحروق ، (٥٦) عينة دم، (٥٤) مسحة من الاذن، (٤٠) عينة ادرار. اظهرت الدراسة ان (49.03%) 108 من العزلات تعود الى جنس *S.aureus* حيث اعطت نتيجة موجبة لفحص الانزيم المخثر للبلازما (Coagulase-Positive Staphylococci) COPS، في حين اعطت ١١٢ (50.9%) من العزلات نتيجة سالبة لفحص الانزيم المخثر للبلازما-Coagulase Negative Staphylococci) CONS. من بين ١٠٨ عزلة بكتيرية من COPS شخصت ٨٥ (78.7%) عزلة بكتيرية على انها بكتريا العنقوديات الذهبية المقاومة للميثيسيلين (MRSA) () methicillin resistance *Staphylococcus aureus* طبقا لاختبار الحساسية للمضادات الحيوية وجهاز الفايتهك vitek 2 system، بينما شخصت ٢٣ (21.9%) عزلة بكتيرية على انها بكتريا العنقوديات الذهبية الحساسة للميثيسيلين (MSSA (methicillin sensitive *Staphylococcus aureus*).